China approves first invasive brain-computer chip: what comes next?

China has approved for clinical use the world's first invasive chip implanted in the human brain for a brain-computer interface (BCI), according to MIT Technology Review in its daily newsletter The Download. The story centers on a resident of Henan province named Dong Hui, who in October, sitting in the courtyard of his own home, decided to try the technology.

What is an invasive brain-computer interface

Brain-computer interfaces fall into two groups: non-invasive ones, such as electroencephalography caps that read signals through the scalp, and invasive ones, which require surgically implanting electrodes directly into brain tissue or onto its surface. Invasive systems deliver a far cleaner and more precise signal because the electrodes sit in direct contact with neurons, rather than picking up activity weakened and distorted by the skull from outside. That is why such devices are usually considered for people with severe motor impairments, such as paralysis, the aftereffects of stroke or spinal cord injuries. A BCI can let them control a computer, a prosthesis or a wheelchair with their thoughts, bypassing damaged nerve pathways.

Why approval in China is a significant milestone

Regulatory approval of an invasive chip means the technology moves from experimental clinical trials to available medical use. In other words, the device can now be implanted in patients outside a narrow circle of research protocols. Until now, the leading developments in this field, above all Elon Musk's Neuralink in the US, have remained at the clinical trial stage with a limited number of patients. Approval of a Chinese counterpart signals that China may be moving faster than Western competitors in the race to commercialize invasive neural interfaces, leaning on its own regulatory and research base.

Key details known so far:

• Location of approval: China, the world's first regulatory approval of an invasive BCI chip.
• Setting of the story: Henan province.
• Protagonist of the piece: a patient named Dong Hui.
• Publication: MIT Technology Review, in its newsletter The Download.

What this means for the future of neurotechnology

Brain-computer interface technology has long been seen as an experimental and extremely niche field, available only to a handful of patients in clinical trials at the world's best medical centers. The move to regulatory approval is a first step toward such devices becoming part of standard medical practice, available to a far broader group of patients with motor impairments. At the same time, it raises questions that are still far from settled: the long-term safety of implanting electrodes in the brain, the risks of infection and tissue rejection, the cost of the surgery and of maintaining the device afterward, and the ethical limits of using the technology beyond strictly medical indications.

For the global neurotechnology race, the Chinese approval may signal acceleration. If one major player shows the way to commercial approval of invasive chips, competitors, above all US companies such as Neuralink and Synchron, as well as research groups in Europe, will come under added pressure to speed up their own regulatory processes and clinical programs, without sacrificing patient safety standards.

The road from a lab prototype to a regulator-approved medical device for invasive neurotechnology usually takes years and runs through successive phases of clinical trials. First they test the basic safety of implantation in a small group of patients, then efficacy and long-term signal stability in a larger sample. That is why reaching the status of a device approved for clinical use is regarded as a significant milestone rather than a routine event: it means the regulator, in this case the Chinese one, judged the accumulated data sufficient to allow wider use of the technology beyond the research centers that took part in the initial trials.

That The Download ran such news also shows that MIT Technology Review's editors see BCI development not as a narrow medical topic but as part of the broader picture of technological progress, alongside advances in generative AI and robotics.